Halozyme Therapeutics ( (HALO) ) has released its Q4 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Halozyme Therapeutics is a biopharmaceutical company known for its innovative ENHANZE drug delivery technology, which facilitates the subcutaneous delivery of injected drugs and fluids, improving patient experiences and outcomes. The company announced record revenue of $1.015 billion for the full year 2024, exceeding its financial guidance for royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. In the fourth quarter, the company’s total revenue increased by 30% year-over-year to $298 million, driven by a 40% rise in royalty revenue. The full-year net income rose by 58% to $444 million, with significant contributions from products like DARZALEX SC, Phesgo, and VYVGART Hytrulo.
Halozyme achieved several strategic milestones in 2024, including regulatory approvals for its ENHANZE technology in both the U.S. and EU, and entered into a $250 million accelerated share repurchase agreement. The company also extended its ENHANZE patent in Europe to 2029, with a similar submission in the U.S., solidifying its leadership in rapid subcutaneous drug delivery. Operating income for the year increased significantly, reflecting efficient cost management with a decrease in cost of sales and steady research and development expenses.
Looking ahead, Halozyme reiterated its 2025 financial guidance, forecasting total revenue growth of 13% to 21%, adjusted EBITDA growth of 19% to 27%, and non-GAAP diluted EPS growth of 17% to 26%. The company expects continued growth in royalty revenue, primarily driven by the increasing adoption of its ENHANZE technology across various therapeutic areas.
With a robust pipeline and strategic partnerships, Halozyme is well-positioned for sustained growth. The company remains focused on leveraging its ENHANZE technology to enhance drug delivery and patient outcomes, aiming to expand its market presence and bring innovative solutions to more patients worldwide.
